Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform
Ketamine therapy for depression seems promising, but how do you know if it’s right for you?
About 30% of people have a genetic variant that impairs the secretion of BDNF, a protein that promotes the growth of neurons.
Since ketamine works by increasing the release of BDNF, people with this gene variant may have a decreased response to the antidepressant effects of ketamine therapy.
HaluGen just expanded its Psychedelics Genetic Test Kit to test for the gene variant! It also tells you how sensitive you’re to classical psychedelics and if you are at risk for schizophrenia, bipolar disorder, or psychosis.